<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1625">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04712357</url>
  </required_header>
  <id_info>
    <org_study_id>CAAE: 34182620.0.0000.5045</org_study_id>
    <nct_id>NCT04712357</nct_id>
  </id_info>
  <brief_title>Clinical Experimentation With Tenofovir Disoproxyl Fumarate and Emtricitabine for COVID-19</brief_title>
  <acronym>ARTAN-C19</acronym>
  <official_title>Clinical, Control, Double-blind, Randomized Experimentation With Tenofovir Disoproxyl Fumarate and Emtricitabine for COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidade Federal do Ceara</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Conselho Nacional de Desenvolvimento Científico e Tecnológico</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>São José Hospital for Infectious Diseases - HSJ</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Central Laboratory of Public Health of Ceará - Lacen-CE</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universidade Federal do Ceara</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical, control, double-blind, randomized trial with tenofovir disoproxyl fumarate and&#xD;
      emtricitabine for Covid-19&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Several therapeutic agents have been evaluated for the treatment of Covid-19, and only one&#xD;
      using an antiviral drug called remdesivir administered intravenously has shown efficacy to&#xD;
      reduce the duration of the disease in 26.7% in critically ill patients. This proposal has as&#xD;
      its primary objective (a) Determine the effect of TDF and TDF + FTC on the duration of&#xD;
      Covid-19 evaluated in the 14th. day of follow-up at the outpatient clinic in the hospital,&#xD;
      duration of the disease observing clinical signs and symptoms, as well as evaluating the&#xD;
      RT-PCR viral load tests on the 1st, 7th, 14th. and 28th. days of the study protocol. In&#xD;
      addition, the proposal assesses several secondary objectives: (b) Assess the action of TDF&#xD;
      and TDF + FTC on the immune response using the rapid ELISA test (IgM / IgG) to be performed&#xD;
      on the 7th. and 28th. days of monitoring the experimental protocol; (c) Determine the effect&#xD;
      of clinical interventions with the drugs TDF and TDF + FTC in the short and medium term on&#xD;
      the viral load of SARS-CoV-2; and (d) Assess the effect of TDF and TDF + FTC on inflammation&#xD;
      biomarkers cytokines and chemokines (IL-6, MCP-3, D-dimer, IL1-RA, IL-10, GCSF, TNF-α, MCP-1&#xD;
      , IL-2R, MIP-1 alpha, IP-10, IL-8, NT-proBNP, Troponin I, CRP and procalcitonin) in the blood&#xD;
      of patients collected in the 1st, 14th. and 28th. study days. The study will be a&#xD;
      prospective, double-blind, placebo control and randomized clinical trial of a total of 219&#xD;
      patients with mild to moderate disease, aged 18 years or over, with clinical signs and&#xD;
      symptoms of Covid-19 and certified after the RT-PCR test for the detection of SARS-CoV-2&#xD;
      viral load. The study will be carried out at the outpatient clinic of Hospital São José,&#xD;
      Fortaleza, CE. The random groups will be: (1) Group - Placebo control (Vitamin C - 500mg /&#xD;
      day, for 10 days); (2) Group - tenofovir disoproxyl fumarate (TDF; 300 mg / day, for 10&#xD;
      days); and (3) Group - TDF + emtricitabine (FTC; 200 mg / day, for 10 days). The study aims&#xD;
      to evaluate the efficacy of tenofovir alone or combined with emtricitabine in the duration of&#xD;
      mild to moderate Covid-19 cases. The study will also assess the effect of drugs on viral load&#xD;
      and immune-inflammatory response. In this sense, the study has the perspective of minimizing&#xD;
      the evolution of the disease to severe cases, thus relieving the collapse of the health&#xD;
      system and minimizing the social, economic and health disorders of the pandemic by&#xD;
      SARS-CoV-2.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 9, 2020</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Control case</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Randomized double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>The time to recovery, defined at day 7 days follow up after enrollment, on which a patient met the criteria for category 1, 2, or 3 on the eight-category ordinal scale.</measure>
    <time_frame>Day 7 follow up after enrollment.</time_frame>
    <description>The categories are as follows: 1 - No signals and symptoms; 2 - One signal or symptom; 3 - Two signals or symptoms; 4 - Three or more signals or symptoms; 5 - Hospitalized, no active medical problems; 6 - Hospitalized, not on oxygen; 7 - Hospitalized, on oxygen; and 8 - Hospitalized, on high flow oxygen.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SARS-CoV-2 RNA viral load measurements change.</measure>
    <time_frame>Change between Day 1 and Day 7 follow up after enrollment.</time_frame>
    <description>Molecular diagnostic analyzes will be done by Real-Time PCR (qPCR) based on official guidelines determined by the American CDC (CDC-006-00019, Revision: 03; https://www.fda.gov/media/134922/download). The nasopharyngeal swab samples collected (Covid-19 test) will proceed to the nucleic acid isolation (NuAc). All qPCR reactions will be by uniplex diagnosis. Results will be reported in copies of RNA / mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with qualitative serum IgM / IgG.</measure>
    <time_frame>Proportion of positive patients at Day 28 for IgM / IgG (N; %).</time_frame>
    <description>The IgM / IgG immune response to SARS-CoV-2 will be qualitative measure using rapid diagnostic test provide by Eco Diagnóstica (Nova Lima, MG, Brazil).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers (IL-6, MCP-3, D-dimer, IL1-RA, IL-10, GCSF, TNF-α, MCP-1, IL-2R, MIP-1 alpha, IP-10, IL-8, NT-proBNP, Troponin I, CRP and procalcitonin) measurements change.</measure>
    <time_frame>Change between Day 1 and Day 14 follow up after enrollment.</time_frame>
    <description>We will use the Luminex XMAP Technology (MAGPIX® System, Merck Co., Kenilworth, NJ) which includes the simultaneous analysis, in the same plasma sample (volume of 25 uL), of a panel of protein markers of pro and anti-inflammatory activity (IL-6, MCP-3, D-dimer, IL1-RA, IL-10, GCSF, TNF-α, MCP-1, IL-2R, MIP-1 alpha, IP-10, IL-8, NT-proBNP, Troponin I). Specific antibodies covalently linked to the carboxylated microspheres containing different specific fluorochromes will be used. Standard curves will be constructed for each protein and then their quantification. Results will be reported in pg / mL.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">219</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Placebo (Vitamin C)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Control placebo (Vitamin C - 500mg / day, for 10 days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tenofovir disoproxyl fumarate (TDF)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tenofovir disoproxyl fumarate (TDF; 300 mg / day, for 10 days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TDF + FTC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tenofovir disoproxyl fumarate (TDF; 300 mg / day, for 10 days) plus emtricitabine (FTC; 200 mg / day, for 10 days)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin C 500 MG Oral Tablet</intervention_name>
    <description>Vitamin C 500 MG per day for 10 days</description>
    <arm_group_label>Placebo (Vitamin C)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir disoproxyl fumarate 300 MG Oral Tablet</intervention_name>
    <description>Tenofovir disoproxyl fumarate 300 MG per day for 10 days</description>
    <arm_group_label>Tenofovir disoproxyl fumarate (TDF)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir disoproxyl fumarate 300 MG plus emtricitabine 200 MG Oral Tablet</intervention_name>
    <description>Tenofovir disoproxyl fumarate 300 MG plus emtricitabine 200 MG per day for 10 days</description>
    <arm_group_label>TDF + FTC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient is &gt; 18 years old&#xD;
&#xD;
          -  Patient diagnosed with COVID-19&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient is already receiving some of the study drugs&#xD;
&#xD;
          -  There is a hospitalization plan in the next 24h&#xD;
&#xD;
          -  Some study treatment is contraindicated&#xD;
&#xD;
          -  Patient has HIV infection&#xD;
&#xD;
          -  Patient has VHB infection&#xD;
&#xD;
          -  Patient lives in another city or state&#xD;
&#xD;
          -  Female patient, pregnant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Aldo AM Lima, Ph.D.</last_name>
    <phone>5585987042833</phone>
    <email>alima@ufc.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alexandre H Binda, Ph.D.</last_name>
    <phone>5585987565695</phone>
    <email>ahavt@ufc.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Núcleo de Biomedicina - NUBIMED</name>
      <address>
        <city>Fortaleza</city>
        <state>Ceará</state>
        <zip>60430270</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aldo A M Lima, PI</last_name>
      <phone>+5585987042833</phone>
      <email>alima@ufc.br</email>
    </contact>
    <contact_backup>
      <last_name>Alexandre Havt Bindá, Co-PI</last_name>
      <phone>+5585987565695</phone>
      <email>ahavt@ufc.br</email>
    </contact_backup>
    <investigator>
      <last_name>Aldo A M Lima, PI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 7, 2021</study_first_submitted>
  <study_first_submitted_qc>January 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 15, 2021</study_first_posted>
  <last_update_submitted>January 14, 2021</last_update_submitted>
  <last_update_submitted_qc>January 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidade Federal do Ceara</investigator_affiliation>
    <investigator_full_name>Aldo Ângelo Moreira Lima</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Tenofovir</keyword>
  <keyword>Emtricitabine</keyword>
  <keyword>COVID-19</keyword>
  <keyword>Clinical trial</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ascorbic Acid</mesh_term>
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

